UNSPSC 51401601: Bentazepam

This classification denotes a sedative, hypnotic, and anxiolytic with the molecular formula C17H16N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 66JKK43S1Z, chemically known as 1,3,6,7,8,9-hexahydro-5-phenyl-2h-(1)benzothieno(2,3-e)-1,4-diazepin-2-one but generally known as bentazepam, which bears US NIH Compound Identifier 34592. European Medicines Agency schedules Bentazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05733MIG.

UNSPSC 51401601 Bentazepam is a Commodity code that in practice encompasses a broader range of pharmaceutical and related health-supply procurement by state and local governments than its narrow drug name suggests. Recent state and local solicitations tagged to this code show purchasing of naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative arrangements, and exploratory procurement of direct-to-manufacturer prescription fulfillment models. The issuing bodies include county health departments, state health and human services commissions, and state cooperative purchasing alliances administering contracts on behalf of multiple participating jurisdictions. Work being solicited ranges from straightforward commodity purchases of named pharmaceutical products with specified quantities and delivery schedules to more complex market-intelligence gathering and system-design efforts focused on alternative pharmacy benefit delivery and cost management models.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to a county health facility and a response deadline of July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, and awards effective July 1, 2026; vendors must work through three authorized wholesalers and meet current Good Manufacturing Practices and Drug Supply Chain Security Act compliance. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription programs, functioning as preliminary market research before formal procurement follows.